Skip to main content

Advertisement

SpringerLink
Log in

Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Epidemiological studies have evaluated the association between CYP17 MspA1 polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. To derive a more precise estimation of the relationship, we performed this meta-analysis. Systematic searches of the PubMed and Medline databases were performed. A total of 35 studies including 22,090 cases and 28,498 controls were identified. Genotype distributions of CYP17 in the controls of all studies were in agreement with Hardy–Weinberg equilibrium (HWE) except for three studies. When all 35 studies were pooled into the meta-analysis, there was no evidence for significant association between CYP17 MspA1 polymorphism and breast cancer risk (for A1/A2 vs. A1/A1: OR = 1.00, 95% CI = 0.96–1.04; for A2/A2 vs. A1/A1: OR = 1.03, 95% CI = 0.97–1.08; for dominant model: OR = 1.01, 95% CI = 0.97–1.05; for recessive model: OR = 1.03, 95% CI = 0.98–1.08). In the subgroup analyses by ethnicity, menopausal status and source of controls, no significant associations were found in all genetic models. When sensitivity analyses were performed by excluding HWE-violating studies, all the results were not materially altered. In summary, the meta-analysis strongly suggests that CYP17 MspA1 polymorphism is not associated with increased breast cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brentano ST, Picado-Leonard J, Mellon SH, Moore CC, Miller WL (1990) Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol Endocrinol 4(12):1972–1979

    Article  CAS  PubMed  Google Scholar 

  2. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94(20):10937–10942

    Article  CAS  PubMed  Google Scholar 

  3. Service RF (1998) New role for estrogen in cancer? Science 279(5357):1631–1633

    Article  CAS  PubMed  Google Scholar 

  4. Fan YS, Sasi R, Lee C, Winter JS, Waterman MR, Lin CC (1992) Localization of the human CYP17 gene (cytochrome P450(17 alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics 14(4):1110–1111

    Article  CAS  PubMed  Google Scholar 

  5. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3(10):1873–1876

    Article  CAS  PubMed  Google Scholar 

  6. Kadonaga JT, Jones KA, Tjian R (1986) Promoter-specific activation of RNA polymerase II transcription by Sp1. Trends Biochem Sci 11(1):20–23

    Article  CAS  Google Scholar 

  7. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57(6):1063–1065

    CAS  PubMed  Google Scholar 

  8. Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE, Ponder BA (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 77(11):2045–2047

    CAS  PubMed  Google Scholar 

  9. Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA (1998) Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 7(10):945–949

    CAS  PubMed  Google Scholar 

  10. Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS (1998) CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7(10):941–944

    CAS  PubMed  Google Scholar 

  11. Bergman-Jungeström M, Gentile M, Lundin AC, Wingren S (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84(4):350–353

    Article  PubMed  Google Scholar 

  12. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59(5):1015–1020

    CAS  PubMed  Google Scholar 

  13. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59(19):4870–4875

    CAS  PubMed  Google Scholar 

  14. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL (1999) CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 59(12):2825–2828

    CAS  PubMed  Google Scholar 

  15. Young IE, Kurian KM, Annink C, Kunkler IH, Anderson VA, Cohen BB, Hooper ML, Wyllie AH, Steel CM (1999) A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 81(1):141–143

    Article  CAS  PubMed  Google Scholar 

  16. Hamajima N, Iwata H, Obata Y, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Ohashi K, Tajima K (2000) No association of the 5′ promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 91(9):880–885

    CAS  PubMed  Google Scholar 

  17. Kuligina ES, Togo AV, Suspitsin EN, Grigoriev MY, Pozharisskiy KM, Chagunava OL, Berstein LM, Theillet C, Hanson KP, Imyanitov EN (2000) CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett 156(1):45–50

    Article  CAS  PubMed  Google Scholar 

  18. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A (2000) Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 9(12):1343–1348

    CAS  PubMed  Google Scholar 

  19. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S (2000) Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 36(18):2375–2379

    Article  CAS  PubMed  Google Scholar 

  20. Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G (2000) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 92(20):1674–1681

    Article  CAS  PubMed  Google Scholar 

  21. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61(2):785–789

    CAS  PubMed  Google Scholar 

  22. McCann SE, Moysich KB, Freudenheim JL, Ambrosone CB, Shields PG (2002) The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J Nutr 132(10):3036–3041

    CAS  PubMed  Google Scholar 

  23. Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG (2003) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 5(2):R45–R51

    Article  CAS  PubMed  Google Scholar 

  24. Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE (2003) CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 88(6):933–936

    Article  CAS  PubMed  Google Scholar 

  25. Tan W, Qi J, Xing DY, Miao XP, Pan KF, Zhang L, Lin DX (2003) Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhonghua Zhong Liu Za Zhi 25(5):453–456

    CAS  PubMed  Google Scholar 

  26. Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC (2003) HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 104(4):450–457

    Article  CAS  PubMed  Google Scholar 

  27. Ahsan H, Whittemore AS, Chen Y, Senie RT, Hamilton SP, Wang Q, Gurvich I, Santella RM (2005) Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res 7(1):R71–R81

    Article  CAS  PubMed  Google Scholar 

  28. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller MW, Muendlein A, Koelbl H (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101(2):264–269

    Article  CAS  PubMed  Google Scholar 

  29. Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR (2004) CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 11(4):380–388

    Article  PubMed  Google Scholar 

  30. Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL, Spurdle AB (2005) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res 7(4):R513–R521

    Article  CAS  PubMed  Google Scholar 

  31. Einarsdóttir K, Rylander-Rudqvist T, Humphreys K, Ahlberg S, Jonasdottir G, Weiderpass E, Chia KS, Ingelman-Sundberg M, Persson I, Liu J, Hall P, Wedrén S (2005) CYP17 gene polymorphism in relation to breast cancer risk: a case-control study. Breast Cancer Res 7(6):R890–R896

    Article  PubMed  Google Scholar 

  32. Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE, Liu F, Zheng F (2005) Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J (Engl) 118(18):1507–1516

    CAS  Google Scholar 

  33. Hopper JL, Hayes VM, Spurdle AB, Chenevix-Trench G, Jenkins MA, Milne RL, Dite GS, Tesoriero AA, McCredie MR, Giles GG, Southey MC (2005) A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancer. Hum Mutat 26(4):298–302

    Article  CAS  PubMed  Google Scholar 

  34. Shin MH, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY, Park SK, Noh DY, Ahn SH, Kim B, Kang D (2005) Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med 37(1):11–17

    CAS  PubMed  Google Scholar 

  35. Verla-Tebit E, Wang-Gohrke S, Chang-Claude J (2005) CYP17 5′-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res 7(4):R455–R464

    Article  CAS  PubMed  Google Scholar 

  36. Hu MB, Xie W, Xiong B, Han DF, Li Y, Feng MH, Zhou YF (2006) Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women. Zhonghua Liu Xing Bing Xue Za Zhi 27(4):351–355

    CAS  PubMed  Google Scholar 

  37. Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J (2006) CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 136(6):1596–1603

    CAS  PubMed  Google Scholar 

  38. Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S (2007) CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet 52(2):159–165

    Article  PubMed  Google Scholar 

  39. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson H, Chanock SJ (2007) CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 16(11):2237–2246

    Article  CAS  PubMed  Google Scholar 

  40. Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S, Eng SM, Wang Q, Gurvich I, Neugut AI, Santella RM, Ahsan H (2008) Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29(4):766–771

    Article  CAS  PubMed  Google Scholar 

  41. Sakoda LC, Blackston C, Doherty JA, Ray RM, Lin MG, Stalsberg H, Gao DL, Feng Z, Thomas DB, Chen C (2008) Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev 17(5):1066–1073

    Article  CAS  PubMed  Google Scholar 

  42. Torresan C, Oliveira MM, Torrezan GT, de Oliveira SF, Abuázar CS, Losi-Guembarovski R, Lima RS, Urban CA, Cavalli IJ, Ribeiro EM (2008) Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med 8(2):65–71

    Article  CAS  PubMed  Google Scholar 

  43. Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K (2009) Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat 114(2):327–338

    Article  CAS  PubMed  Google Scholar 

  44. Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crinò L, Barberini F, Rulli A (2009) CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9:115

    Article  PubMed  Google Scholar 

  45. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism. Breast Cancer Res Treat. doi:10.1007/s10549-009-0490-2

  46. Samson M, Rama R, Swaminathan R, Sridevi V, Nancy KN, Rajkumar T (2009) CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women. Asian Pac J Cancer Prev 10(1):111–114

    PubMed  Google Scholar 

  47. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T (2009) Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 125(4):837–843

    Article  CAS  PubMed  Google Scholar 

  48. Ye Z, Parry JM (2002) The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17(2):119–126

    Article  CAS  PubMed  Google Scholar 

  49. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1):101–129

    Article  Google Scholar 

  50. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748

    CAS  PubMed  Google Scholar 

  51. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

    Article  CAS  PubMed  Google Scholar 

  52. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are fully responsible for all content and editorial decisions and did not receive financial support or other form of compensation related to the development of the manuscript.

Author information

Authors and Affiliations

  1. Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China

    Chen Mao, Xi-Wen Wang, Ru-Yan Liao & Qing Chen

  2. Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    Ben-Fu He & Rong-Cheng Luo

  3. Department of Medical Oncology, Cancer Hospital, Fudan University, Shanghai, China

    Li-Xin Qiu

  4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    Li-Xin Qiu

Authors
  1. Chen Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xi-Wen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ben-Fu He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li-Xin Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ru-Yan Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rong-Cheng Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qing Chen.

Additional information

Chen Mao and Xi-Wen Wang contributed equally to this work and should be considered as co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mao, C., Wang, XW., He, BF. et al. Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls. Breast Cancer Res Treat 122, 259–265 (2010). https://doi.org/10.1007/s10549-009-0695-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0695-4

Keywords

Search

Navigation